GRTX Galera Therapeutics Inc

USD 0.15 -0.03 -16.576087
Icon

Galera Therapeutics Inc (GRTX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.1535

-0.03 (-16.58)%

USD 0.01B

2.40M

N/A

USD 0.00 (-100.00%)

Icon

GRTX

Galera Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 0.15
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.01B

USD 0.00 (-100.00%)

USD 0.15

Galera Therapeutics Inc (GRTX) Stock Forecast

N/A

Based on the Galera Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Galera Therapeutics Inc is not available over the next 12 months. Galera Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Galera Therapeutics Inc is Bearish, which is based on 1 positive signals and 9 negative signals. At the last closing, Galera Therapeutics Inc’s stock price was USD 0.1535. Galera Therapeutics Inc’s stock price has changed by -36.70% over the past week, -38.62% over the past month and -93.76% over the last year.

No recent analyst target price found for Galera Therapeutics Inc
No recent average analyst rating found for Galera Therapeutics Inc

Company Overview Galera Therapeutics Inc

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismut...Read More

https://www.galeratx.com

P.O. Box 134, Malvern, PA, United States, 19355

31

December

USD

USA

Adjusted Closing Price for Galera Therapeutics Inc (GRTX)

Loading...

Unadjusted Closing Price for Galera Therapeutics Inc (GRTX)

Loading...

Share Trading Volume for Galera Therapeutics Inc Shares

Loading...

Compare Performance of Galera Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for GRTX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Galera Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S -1.36 (-1.05%) USD554.45B 46.01 4.80

ETFs Containing GRTX

Symbol Name GRTX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Galera Therapeutics Inc (GRTX) Stock

Stock Target Advisor's fundamental analysis for Galera Therapeutics Inc's stock is Bearish.

Unfortunately we do not have enough data on GRTX's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on GRTX's stock to indicate what its average analyst target is.

GRTX stock's Price/Earning ratio is -99,999.99. Our analysis grades GRTX stock's Price / Earning ratio at A+. This means that GRTX stock's Price/Earning ratio is above 3.000000000000003% of the stocks in the Biotechnology sector in the NSD exchange. Based on this GRTX may be undervalued for its sector.

The last closing price of GRTX's stock was USD 0.15.

The most recent market capitalization for GRTX is USD 0.01B.

Unfortunately we do not have enough analyst data on GRTX's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Galera Therapeutics Inc's stock.

As per our most recent records Galera Therapeutics Inc has 31 Employees.

Galera Therapeutics Inc's registered address is P.O. Box 134, Malvern, PA, United States, 19355. You can get more information about it from Galera Therapeutics Inc's website at https://www.galeratx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...